Your Article Summary
See Latest ArticlesCurrent use of immunosuppressive agents in inflammatory bowel disease patients in East China
World Journal of Gastroenterology, 06/29/09
Huang LJ et al. - Immunosuppressive agents are used less frequently to treat IBD patients from East China compared with Western countries. Monitoring immunosuppressive agent use is recommended to optimize dispensation of drugs for IBD in China.
Related Articles
IBD drugs and cancer risk
JAMA, 11/18/09
Relevance Score: 87%
Pediatric Inflammatory Bowel Disease: Highlighting Pediatric Differences in IBD
Gastroenterology Clinics of North America, 11/13/09
Relevance Score: 87%
Diagnostic Role and Clinical Association of ASCA and ANCA in Brazilian Patients with Inflammatory Bowel Disease
Digestive Diseases and Sciences, 10/19/09
Relevance Score: 87%
Safety Profile of IBD Therapeutics: Infectious Risks
Gastroenterology Clinics of North America, 11/17/09
Relevance Score: 85%
Safety Profile of IBD: Lymphoma Risks
Gastroenterology Clinics of North America, 11/16/09
Relevance Score: 85%
Today in Inflammatory Bowel Dz...keeping you current
Receive free subspecialty "5-minute updates" via email
Clinical outcome of newly diagnosed Crohns disease: a comparative, retrospective study before and after infliximab availability
Alimentary Pharmacology and Therapeutics, 12/17/09
Anti-fibrotic agents for the treatment of Crohn's disease - lessons learnt from other diseases
Alimentary Pharmacology and Therapeutics, 12/17/09
Lethal neuroendocrine carcinoma in ulcerative colitis
World Journal of Gastroenterology, 12/17/09
Today in Pharmacology/kinetics...keeping you current
Receive free subspecialty "5-minute updates" via email
A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer
Investigational New Drugs, 12/17/09
Pilot study: the use of sulfasalazine for the treatment of acute pouchitis
Alimentary Pharmacology and Therapeutics, 12/17/09
Clinical outcome of newly diagnosed Crohns disease: a comparative, retrospective study before and after infliximab availability
Alimentary Pharmacology and Therapeutics, 12/17/09